The many roads to cross-presentation

Copyright 2005 The Rockefeller University Press.
The many roads to cross-presentation

Tom Groothuis and Jacques Neefjes

Cross-presentation of extracellular antigens by MHC class I molecules is required for priming cytotoxic T lymphocytes (CTLs) at locations remote from the site of infection. Various mechanisms have been proposed to explain cross-presentation. One such mechanism involves the fusion of the endoplasmic reticulum (ER) with the endosomal–phagosomal system, in which the machinery required for peptide loading of MHC class I molecules is introduced directly into the phagosome. Here, we discuss the evidence for and against the ER–phagosome concept as well as other possible mechanisms of cross-presentation.

The scientific community warmly receives data that support new theories addressing major problems in a field. These theories can sometimes become dogma—textbook knowledge—even when based on inconclusive data. Such data are difficult to correct with essentially negative results, and such results equally are difficult to publish. A recent publication by Touret et al. (1) is an exception to this rule. In this study, the concept of ER–phagosome fusion was tested and refuted, leaving open several alternative routes for cross-presentation. Here we discuss recent studies on the biology of cross-presentation and explain why the ER–phagosome mechanism is unlikely to contribute to this process.

Classical and cross-presentation by MHC class I molecules

Cross-presentation is the process by which extracellular antigens, which are normally presented in association with MHC class II molecules, are instead presented by MHC class I molecules. This differs from the classical MHC class I processing pathway in which MHC class I molecules present antigens that are synthesized within the cell. Classical MHC class I antigen presentation begins with the degradation of intracellularly synthesized proteins by the proteasome. Only a fraction of the peptide fragments that result from this degradation survives complete destruction and is transported into the ER by the peptide transporter TAP (transporter associated with antigen presentation) (2). In the ER, the peptides are loaded onto newly synthesized MHC class I molecules, and these complexes are then transported to the cell surface (3). In contrast, the MHC class II processing pathway is dedicated to the presentation of exogenous and self-antigens that are degraded in the endocytic pathway. The proteases involved in endocytic degradation (cathepsins) are different than those used in the MHC class I pathway. Peptides are formed as intermediates during late endosomal protein degradation and are loaded onto MHC class II molecules in a reaction catalyzed by the chaperone protein HLA-DM before transport to the plasma membrane (4). MHC class I and MHC class II molecules thus sample antigenic information from different sources, intracellular and extracellular antigens, respectively. A major exception occurs during cross-presentation.

In vivo, DCs—the major cell type responsible for cross-priming—acquire endogenous antigens from infected cells in the periphery, and then migrate to the lymph nodes where they display antigenic peptides in association with MHC class I molecules. MHC class I–peptide complexes are recognized by antigen-specific CTLs, which become activated and expand in response to antigen recognition (5). In this scenario, the source of antigens (intracellular, but from a different cell, or extracellular as in vaccination settings) is distinct from that usually sampled by the classical MHC class I antigen presentation pathway (intracellular antigens within the antigen presenting cell). Hence the mechanism of antigen degradation and delivery of the peptide to MHC class I molecules is also likely to be different. The mechanism of cross-presentation has garnered much interest in recent years, in part because cross-presentation is likely to be important in activating CTLs in response to vaccine antigens. But the mechanism (or mechanisms) has yet to be definitively defined.
Deciphering mechanism

There are many difficulties inherent in defining the mechanism of cross-presentation. One is the source of antigen. In vaccine studies, heat shock proteins (such as gp96), apoptotic bodies, the content of late endosomes (exosomes), cell lysates, intact cells, peptides, antibodies, and bead-associated proteins have all been used as sources of antigen (3). Most of these antigens are extracellular but are derived from an intracellular source (the infected cell) and are likely liberated as a result of cell lysis. But intracellular antigens from intact cells can also be cross-presented. One way this could occur is through the swapping of intracellular peptides through gap junctions (6). It has been known for a long time that most tissue cells are electrically coupled with their neighboring cells through gap junctions, small channels that connect the cytosols of adjacent cells. Dendritic cells and activated monocytes can also establish gap junctions with other cells—including infected cells—and thereby acquire antigenic fragments for cross-presentation (6). Notably, tumors usually close their gap junctions, opting to live solitary lives. This may explain why tumors often elicit poor CTL responses. Still, this immunological coupling through gap junctions could explain cross-presentation under conditions in which the antigen-expressing cell does not release the antigen into the extracellular milieu.

Coupling of antigen-containing cells and APCs by gap junctions does not, however, explain how extracellular antigens, such as those used in vaccination studies, are cross-presented. Previous studies with a variety of extracellular antigens have demonstrated crucial roles for TAP (7) and the proteasome (8, 9) in cross-presentation. One interpretation of these results is that these antigens (or peptides derived thereof) somehow enter the cytosol of DCs, making them available for proteasomal degradation, transport into the ER, and presentation on MHC class I molecules. Another possibility lies in the observation that MHC class I molecules can be recycled from the cell surface along the endocytic MHC class II pathway and exchange endogenous for exogenous peptides en route (10). Notably, TAP and proteasome activities are both required for surface expression of MHC class I molecules (11), without which the recycling pool cannot exist. Hence, the involvement of TAP or proteasomes in cross-presentation is not necessarily evidence for entry of exogenous antigens into the cytosol of DCs, but it also does not exclude this possibility. Recent studies revealed a role for a putative endocytosis signal in MHC class I (12) and for endosomal proteases (13) in cross-presentation, which support a role for the recycling pathway. In this model, antigens would be degraded by endocytic proteases rather than the proteasome, and thus some antigens that would normally be presented in the classical pathway might not survive to be cross-presented.

Other mechanisms besides the recycling pathway might also result in cross-presentation (Fig. 1). For example, exosomes—vesicles derived from the interior of endocytic structures that are released by many cell types—can also induce CTL responses by cross-presentation (14). Whether simple binding of these small vesicles, which contain MHC class I–peptide complexes, to the plasma membrane of DCs suffices to trigger CTL activation is unclear and the mechanism is still poorly defined. In addition, various experiments have shown that extracellular proteins can be transferred from endosomes into the cytosol of DCs (9), although how this occurs is unclear. It might involve dissolution of the endocytic membrane or specific protein transporters that pump the antigen out of endosomes and/or lysosomes. Note that solubilization of an antigen-containing endocytic structure would liberate endosomal proteases and likely result in the death of the cross-presenting cell.

ER-phagosome model

Recently, at least three papers offered an alternative model of cross-presentation: direct fusion of phagosomes with the ER membrane. In other words, they propose that the phagosomal membrane is formed—entirely or in part—from the ER membrane. As a consequence of this fusion, the enzymatic machinery required for the release of phagosomal proteins into the cytosol (the ER-associated degradation (ERAD) system) and the MHC class I loading machinery become an integral part of the endocytic system (15, 16). The ERAD system, which shuttles misfolded proteins from the ER into the cytosol for proteasomal degradation, would thus become the phagosome-to-cytosol protein transporter mentioned earlier. This model offers a new mechanistic explanation for MHC class I cross-presentation, but has recently been tested and refuted (1). Moreover, we suggest that this model is problematic for other reasons and is thus unlikely to contribute significantly to cross-presentation in vivo.

Early studies of bacteria that live and propagate in phagosomes suggested that the phagosomal membrane was largely derived from the plasma membrane, with a minor contribution from other endocytic structures including late endosomes, lysosomes, and MIIIGs (vesicles that accumulate MHC class II molecules) (17). But more recent studies—most of which used synthetic beads as a substitute
for antigen—found ER-specific proteins such as calnexin, calreticulin, and the ERAD translocon sub-unit Sec61p in the isolated bead-containing fractions (18). Based on this finding, the authors concluded that the membrane of the bead-containing phagosome (beadosome) was derived, at least in part, from the ER membrane. But these results could also be explained by contamination of the beadosome membrane with ER-derived vesicles during purification.

Electron microscopy has also been used to show that the phagosomal membrane is formed from the ER. Gagnon et al. showed that the ER membrane and the plasma membrane fused at the site of bead contact (18). However, in that study the content of the ER lumen did not diffuse into the extracellular medium and membrane-like structures that separated the ER from the phagocytic cup were still visible, suggesting the possibility that bona fide fusion did not occur. The authors also noted that an ER-specific enzymatic activity (glucose-6-phosphatase (G6Pase)) was detected in the beadosome. Since then, several new isotypes of G6Pase have been identified, only one of which contains an ER retention motif (19). Thus, it is possible that this enzyme might be more widely localized than it was originally thought to be.

Despite these caveats, the concept that the ER contributes to the phagosomal membrane is highly attractive as it provides a mechanistic explanation for the cross-presentation of extracellular proteins. More recently, two papers were published claiming that this route was operational when antigens were given in association with 3-µm beads (15, 16). Whether other antigen cocktails utilize the same pathway was not addressed. These studies also failed to satisfactorily address the underlying issue of ER contamination, which renders the localization of ER-specific markers (such as Sec61, TAP, tapasin, calreticulin, and Erp57) in purified bead-containing vesicles open to alternative interpretations. Indeed, Guermonprez et al. used cryo-electron microscopy to detect the ER marker calreticulin directly by antibodies (10). They failed to detect these at the phagosomal membrane but only “in close apposition” in the ER.

In the study by Houde et al., the proteasome and undefined polyubiquitinated proteins were co-isolated with the beadosome, and this resulted in a rather eccentric model (16). In this model, the bead-associated antigens are pumped from the beadosome into the cytosol by the Sec61-containing ERAD system (20) and are ubiquitinated by beadosome-associated enzymes during retrotranslocation. In a sort of a coupled reaction, the retrotranslocated antigens are degraded by the beadosome-associated protea-

some, and the resulting peptide fragments associate exclusively with TAP complexes located in the beadosome. If correct, this suggests that the physical laws for Brownian motion do not apply to bead-derived antigens since they and their degradation products “know” where to be targeted to: beadosome-associated proteasomes and TAP, respectively. Ackerman et al. used another approach to test the feasibility of direct fusion of the ER to bead-containing phagosomes (21). They performed the same type of experiments as discussed above (with similar problems) but also showed that a soluble viral TAP inhibitor (US6) could access a macropinocytic compartment and block cross-presentation of a cointernalized soluble protein. However, a subsequent paper by the same authors showed that exogenous proteins could follow a retrograde transport pathway from endosomes, through the Golgi and back into the ER (22). This suggests that soluble proteins might be cross-presented as a result of their ability to directly access the MHC class I processing machinery in the ER lumen. Retrograde transport through the Golgi could thus explain how soluble antibodies are able to gain access to the ER and why soluble US6 inhibits cross-presentation. In other words, it does not prove the existence of a mixed ER–phagosome compartment, but rather reveals yet another potential mechanism by which extracellular antigens could be cross-presented.

So does the ER–phagosome exist? As mentioned earlier, experiments using bacterial phagosomes suggested that the plasma membrane rather than the ER was the primary source of phagosomal membranes (17, 23, 24). In their new study, Touret et al. rigorously tested the origin of the phagosomal membrane around ingested beads or bacteria (1). The experiments performed in earlier studies (15, 16, 18) were largely repeated by Touret et al. Quantitative immunolabeling for ER markers and G6Pase activity measurements showed no evidence for a contribution of the ER to the phagosomal membrane. In addition, extracellular dyes were shown to be constrained in the phagosome and did not diffuse into the ER, as would be expected if the ER–lumen was in (even temporal) continuum with the forming beadosome. The authors performed a plethora of experiments, none of which provided evidence for ER–phagosome fusion (1).

One experiment deserves special attention because of its elegance. In this experiment, the biotin-binding protein avidin was expressed with an ER retention signal (KDEL) in a macrophage cell line. Beads coated with biotin were then phagocytosed by the cells, and direct contact between the ER-retained avidin and bead-associated biotin was quantified.
No avidin–biotin interactions were observed, casting more doubt on the concept of direct interaction between the ER and phagosomes (1). Touret et al. conclude that the plasma membrane and the endocytic pathway are the major sources for phagosomal membranes, with no significant contribution by the ER (estimated between 0 and 10%) (1).

**Calculating the odds of ER-phagosome fusion**

The feasibility of this model may be deduced by “number crunching” according to Yewdellian philosophy (25). An estimation of the numbers of MHC class I molecules entering a 3-µm beadosome (15, 16) from the ER and the numbers of molecules required to initiate cross-presentation may help reveal whether the ER–phagosome fusion mechanism is plausible. If ER-derived membrane constituted 10% of the phagosomal membrane, would this suffice for efficient cross-presentation? If one approximates that an average rounded cell has a radius of ~10 µm, then by comparing the surface area ($4\pi r^2$) of the cell with that of the 3-µm bead-induced phagosome, one can calculate that ~2% ($[1.5/10]^2$ or ~2 x 10$^{-2}$) of the plasma membrane is contributed to the membrane of the 3-µm beadosome (radius of ~1.5 µm). The ER constitutes ~60% of cellular lipids (compared with the plasma membrane’s 5%) (26), which means that 0.16% ($2 \cdot 10^{-2} \times [5/60]$) of the ER membrane would be donated to each beadosome, if the beadosome membrane was composed entirely of ER-derived membrane. MHC class I molecules have a half-life of over 12 h (although this varies somewhat in different cell types) but are available for peptide loading in the ER for 30 min or less (27). Even with this conservative estimation, this implies that at every moment less than 100,000 peptide-receptive MHC class [I molecules are present, raising doubt on the practicality of this mechanism.
I molecules would be located in the ER of a DC that contains a total of 2 million MHC class I molecules. Of these, 16 \(100,000 \times 2 \cdot 10^{-2} \times \left[\frac{5}{60}\right] \times 0.1\) MHC class I molecules would enter one 3-µm phagosome at a 10% contribution of the ER and 160 molecules at a 100% contribution. These numbers would decrease ninefold for a 1-µm bead and even more for soluble antigens and immune complexes.

A minimum of 40 and 400 MHC–peptide complexes is reported to be required for stimulation of primed and naive T cells, respectively (28). Based on our calculations, T cell activation would thus occur only if nearly all the peptides delivered into the cytosol from bead-derived phagosomes found their way back into phagosomes without any competition from endogenous peptides. Given that endogenous peptides are present in the cytosol even before exogenous antigens are degraded (2), beadosome-derived antigenic peptides would likely be out-competed by endogenous peptides and would thus return to the beadosomes too late to load the few ER-derived MHC class I molecules at that location. However, if the ER translocon protein Sec61, which also inserts polypeptides into the ER lumen as they are translated, is introduced in the phagosome, as suggested by previous studies (15, 16, 18), then translation of novel proteins could continue at the phagosomal membrane and result in the deposition of de novo–translated proteins directly into the phagosome. The phagosome would thus mimic the ER by allowing the introduction of nascent proteins (including MHC class I molecules), but no data are available on this point.

Our own electron microscopy analysis shows that typical ribosomal structures can be found associated to the ER membrane, but no such structures were localized to the beadosomal membrane (Fig. 2). Bead-induced cross-presentation therefore must rely on the few ER-derived MHC class I molecules, or on cell surface–derived MHC class I molecules (2 million \(\times 2 \cdot 10^{-2} = 40,000\) surface MHC class I molecules in a 3-µm beadosome) for cross-presentation of phagosomal antigens. Surface MHC class I molecules can efficiently exchange peptides between pH 4.5 and 5.5 (10), suggesting that peptide loading could take place in the phagosomal environment, although the loading would be considerably less efficient than in the “specialized” MHC class I–loading complex in the ER. However, inefficiency would not be a major issue in the recycling pathway as 40,000 surface-derived MHC class I molecules would be available to bind peptides, whereas only 160 MHC class I molecules would be available if the beadosome membrane were derived entirely from the ER.

**Concluding considerations**

Various studies have reached diametrically opposing conclusions regarding the origin of the phagosomal membrane—a crucial question underlying the mechanism of cross-presentation. Gagnon et al. showed an ER contribution to the phagosomal membrane in macrophages, but not in other cells such as neutrophils (18). These experiments could also not be confirmed in macrophages and DCs in the recent study by Touret et al. (1). Although the studies that argue for the ER–phagosomal fusion mechanism received much attention, they did not address the mechanism of cross-presentation of physiological antigens, including antibody-bound antigens (29), soluble antigens (30), and intracellular antigens (6), which might all follow distinct pathways of degradation inside the cell. Furthermore, a simple calculation predicts that cross-presentation via the ER–phagosome pathway would be highly inefficient, if at all possible.

Apart from being an interesting biological question, cross-presentation has direct consequences for vaccination strategies aimed at inducing CTL responses. These vaccines should be able to induce potent CTL responses and T cell memory, and the specificity of the CTL response will result from the
cross-presentation of antigenic fragments. Understanding the mechanism(s) of cross-presentation will help rationalize vaccine development and improve the chances to arrive at successful antiviral and antitumor vaccines.

ACKNOWLEDGMENTS

This work was supported by grants from the Dutch Cancer Society KWF. We thank Alexander Griekspoor, Helen Pickersgill, and Andra Neefjes-Borst for critically reading the manuscript. We thank Hans Jansen for the electron microscopy.

REFERENCES


